By combining TSP2 with FIB‐4, it may be possible to identify patients at a low risk of developing HCC post‐SVR, potentially allowing for a longer period between follow‐up visits compared with groups displaying other marker profiles. The gene discussed is THBS2; the disease is hepatocellular carcinoma.